Adaptimmune Therapeutics plc

  • Home
  • Our Company
    • Overview arrow_forward
    • Partners arrow_forward
    • Board of Directors arrow_forward
    • Leadership Team arrow_forward
    • Scientific Advisory Board arrow_forward
    • Perspectives arrow_forward
  • Pipeline
    • Clinical Pipeline arrow_forward
    • Afami-cel arrow_forward
    • ADP-A2M4CD8 arrow_forward
    • Preclinical Pipeline arrow_forward
  • Technology
    • Overview arrow_forward
    • Manufacturing arrow_forward
    • Publications arrow_forward
  • Patients & Families
    • Overview arrow_forward
    • Taking Part in Our Clinical Trials arrow_forward
    • Cancer Info arrow_forward
    • Videos arrow_forward
    • Engagement with Patient Organizations arrow_forward
  • Clinical Trials
    • Overview arrow_forward
    • Expanded Access Policy arrow_forward
  • Investors & Media
    • Overview arrow_forward
    • News Center arrow_forward
    • Financial Info and Governance arrow_forward
    • Stock Data arrow_forward
    • SEC Filings arrow_forward
  • Contact
  • Careers
    • Overview arrow_forward
    • US Careers arrow_forward
    • UK Careers arrow_forward

Press Releases

Investors & Media

Investors & Media

  • Overview
  • News Center
    • Media
    • Corporate Presentations
    • Press Releases
    • Publications
    • Events
    • Email Alerts
  • Financial Info and Governance
    • Company Information
    • Leadership Team
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Annual Shareholder Meeting
    • FAQ
    • Contacts
    • Adaptimmune Ltd Report
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • News Center

  • Media
  • Corporate Presentations
  • Press Releases
  • Publications
  • Events
  • Email Alerts
Sep 07, 2021 7:00am EDT

Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies

Sep 05, 2021 6:15am EDT

Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit

Aug 09, 2021 4:00pm EDT

Adaptimmune Reports Second Quarter Financial Results and Business Update

Jul 28, 2021 8:11am EDT

Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9, 2021

May 19, 2021 5:00pm EDT

Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial

May 11, 2021 8:00am EDT

First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model

May 06, 2021 7:30am EDT

Adaptimmune Reports First Quarter Financial Results and Business Update

Apr 27, 2021 4:30pm EDT

Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT

Apr 22, 2021 8:00am EDT

Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021

Feb 25, 2021 7:30am EST

Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update

RSS
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...25
  • Next
Adaptimmune Therapeutics plc
Privacy Policy Disclaimer Search Sitemap Terms of Use Supply Terms Cookie Policy Manage Cookie Preferences
Linedin Twitter Youtube
© 2023 Adaptimmune Therapeutics plc. All Rights Reserved.